Market Segmentation:
- By Disease Type
- Retinitis Pigmentosa
- Stargardt Disease
- Leber Congenital Amaurosis
- Usher Syndrome
- Cone-Rod Dystrophy
- By Gene Mutation
- RPE65 Mutation
- ABCA4 Mutation
- USH2A Mutation
- RPGR Mutation
- CNGA3 Mutation
- CNGB3 Mutation
- Others (PRPH2, RHO, etc.)
- By Treatment Type
- Gene Therapy
- Stem Cell Therapy
- Nutritional Supplements
- Low-Vision Aids
- Others (Retinal Implants, Optogenetics, etc.)
- By Route of Administration
- Intravitreal
- Subretinal
- Intravenous
- Others (Topical, Oral, etc.)
- By End-User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Research Institutes
- By Distribution Channel
- Direct Tenders
- Retail Sales
- Others (E-commerce, Hospital Pharmacies, etc.)
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Inherited Retinal Disease industry is estimated to be around USD 2.1 billion.
Increasing prevalence, Aging population, Advancements in gene therapies, Improved diagnostics, Growing awareness, Rising healthcare expenditure, Increasing investments in research and development, Expansion of genetic testing services, Development of novel treatment modalities, Increasing adoption of personalized medicine approaches.
High treatment costs and affordability issues, Regulatory challenges and ethical concerns, Limited availability of gene therapies, Complex genetic nature of IRDs, Lack of awareness in certain regions, Challenges in disease diagnosis, Reimbursement issues.
The retinitis pigmentosa segment is the leading component segment in the Inherited Retinal Disease Market due to its high prevalence and ongoing research efforts for effective treatments.
Spark Therapeutics (Novartis), ProQR Therapeutics, AGTC, Nightstar Therapeutics (Biogen), Horama, Sanofi, Editas Medicine, Acucela, Shire (Takeda), Novelion Therapeutics, Kubota Vision, Regenxbio, GenSight Biologics, Nanoscope Therapeutics, Ocugen, Allergan (AbbVie), Ionis Pharmaceuticals, Alkeus Pharmaceuticals, Gemini Therapeutics, Ophthotech.
The global Inherited Retinal Disease Market is projected to grow at a CAGR of 18.2% during the forecast period of 2024-2031, reaching a market size of US$ 8.0 billion by 2031.
Increasing prevalence, Aging population, Advancements in gene therapies, Improved diagnostics, Growing awareness, Rising healthcare expenditure, Increasing investments in research and development, Expansion of genetic testing services.